Patients with type 2 diabetes and cardiovascular disease who received empagliflozin had lower rates of cardiovascular-related and all-cause mortality than those on placebo, an industry-funded study found.
Once-weekly glucagon-like peptide 1 (GLP-1) receptor agonists lower HbA1c without increasing body weight, a review found.
Home use of a closed-loop insulin delivery system, or artificial pancreas, appeared to be effective in patients with type 1 diabetes, according to 2 recently published reports conducted under regular living conditions.
This month's quiz asks readers to evaluate a 60-year-old woman who has gastroparesis associated with long-standing type 2 diabetes mellitus.
More intensive behavioral programs were more effective at helping patients with type 2 diabetes lower their HbA1c levels but not those with type 1, according to systematic analyses recently published in Annals of Internal Medicine.
Review: Type 2 diabetes screening does not reduce mortality but treating dysglycemia delays onset of diabetes
A systematic evidence review by the U.S. Preventive Services Task Force found no evidence of mortality benefit from screening for diabetes, based on 2 large randomized controlled trials conducted in the United Kingdom.
The FDA on Sept. 10 released a strengthened warning on canagliflozin (Invokana, Invokamet) about increased risk of bone fractures and decreased bone mineral density.
Insulin degludec injection (Tresiba) and insulin degludec/insulin aspart injection (Ryzodeg 70/30) were approved by the FDA on Sept. 25.